Approval · Notice of Compliance 23213 · 2020
XIIDRA: Notice of Compliance 23213
Issued February 13, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23213
- Date
- February 13, 2020
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the product monograph and package insert. the labelling update includes post-market safety information with respect to hypersensitivity and reviisons to the mechanism of action section of the product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XIIDRA | Not yet assigned | — |
Medicinal ingredients
- LIFITEGRAST 5 PER